© JUN 2021 | IRE Journals | Volume 4 Issue 12 | ISSN: 2456-8880

Machine Learning Models for Early Detection of Cardiovascular Diseases: A Systematic Review

DAMILOLA OSAMIKA[1], BAMIDELE SAMUEL ADELUSI[2], MARIATHERESA CHINYEAKA KELVIN-AGWU[3], ASHIATA YETUNDE MUSTAPHA[4], NURA IKHALEA[5]

[1]*Department of Environmental Health, Margaret Mosunmola College of Health Science and Technology, Nigeria*

[2]*Software Engineer, SigmaXplus Solutions LLC, USA*

[3]*Independent Researcher, Lagos Nigeria*

[4]*Kwara State Ministry of Health, Nigeria*

[5]*Independent Researcher, Texas, USA*

Abstract- Cardiovascular diseases (CVDs) are the leading cause of morbidity and mortality worldwide, emphasizing the need for early detection to improve patient outcomes and reduce healthcare costs. Machine learning (ML) has emerged as a transformative tool for predicting and diagnosing CVDs by leveraging vast datasets, including electronic health records (EHRs), medical imaging, wearable device data, and genomic information. This systematic review explores the latest advancements in ML models for early CVD detection, highlighting key algorithms, data sources, and evaluation metrics. Supervised learning models such as Logistic Regression, Support Vector Machines (SVM), Random Forest, and Gradient Boosting have shown promise in risk prediction, while deep learning techniques, including Convolutional Neural Networks (CNN) for imaging analysis and Long Short-Term Memory (LSTM) networks for time-series data, enhance diagnostic accuracy. Additionally, feature selection and engineering methods improve the predictive performance of ML models by identifying critical risk factors from structured and unstructured data. Despite significant progress, challenges remain, including data quality issues, model interpretability, generalizability across diverse populations, and regulatory compliance with healthcare standards such as GDPR and HIPAA. Bias in ML models and concerns over patient privacy must also be addressed to ensure ethical deployment. Future research should focus on integrating ML with personalized medicine, federated learning for secure data sharing, and real-time monitoring through IoT-enabled devices. Developing explainable AI models and robust regulatory frameworks will further enhance clinical adoption and patient trust. This review underscores the potential of ML in revolutionizing early CVD detection and provides insights for researchers, clinicians, and policymakers to harness AI-driven innovations for improving cardiovascular health outcomes.

Indexed Terms- Machine Learning, Cardiovascular Diseases, Early Detection, Deep Learning, Predictive Analytics, Healthcare AI, Electronic Health Records

I. INTRODUCTION

Cardiovascular diseases (CVDs) remain the leading cause of morbidity and mortality worldwide, accounting for approximately 17.9 million deaths annually, according to the World Health Organization (WHO). These diseases encompass a range of conditions, including coronary artery disease, stroke, heart failure, and hypertension, which collectively impose a significant economic burden on healthcare systems. The rising prevalence of CVDs is primarily attributed to aging populations, sedentary lifestyles, poor dietary habits, and increasing rates of obesity and diabetes (Elagizi *et al*., 2020). Despite advancements in treatment, late-stage diagnosis and delayed interventions continue to contribute to poor patient outcomes, highlighting the urgent need for improved early detection and prevention strategies.

Early detection of CVDs plays a crucial role in reducing morbidity and mortality by enabling timely interventions and personalized treatment plans. Traditional diagnostic methods, such as electrocardiograms (ECG), echocardiography, and biochemical markers, while effective, often require clinical visits and expert interpretation, leading to delays in diagnosis (Serhani *et al*., 2020; Rudski *et al*., 2020). Moreover, many patients remain asymptomatic until the disease has progressed significantly, limiting the window for effective preventive measures. Identifying high-risk individuals at an early stage can facilitate lifestyle modifications, pharmacological interventions, and targeted therapies, ultimately reducing hospitalizations, healthcare costs, and fatal outcomes. Machine Learning (ML) offers a promising approach to enhancing early detection capabilities by leveraging large-scale medical data to improve risk assessment and predictive modeling (Bayyapu *et al*., 2019; Ahmed *et al*., 2020).

Machine Learning has emerged as a transformative tool in healthcare, offering the ability to analyze complex and high-dimensional data with superior accuracy and efficiency (Suryadevara and Yanamala, 2020). ML algorithms can process vast amounts of structured and unstructured medical data, including electronic health records (EHRs), genetic information, wearable device data, and imaging results, to identify patterns indicative of CVD risk. Supervised learning techniques, such as logistic regression, support vector machines (SVM), random forest, and gradient boosting, have demonstrated significant success in predicting CVD outcomes. Additionally, deep learning methods, including convolutional neural networks (CNN) for medical imaging and long short-term memory (LSTM) networks for time-series analysis, offer advanced diagnostic capabilities. ML models enhance traditional risk stratification tools by incorporating real-time monitoring and personalized risk assessment. By integrating ML with wearable technologies and mobile health applications, continuous tracking of physiological parameters such as heart rate variability, blood pressure, and oxygen saturation can provide early warnings of cardiac abnormalities (Hurley *et al*., 2020; Chen *et al*., 2021). Furthermore, AI-driven decision support systems aid clinicians in interpreting complex datasets, improving diagnostic accuracy, and optimizing treatment strategies. However, the adoption of ML in CVD detection also presents challenges, including data privacy concerns, model interpretability, and the need for regulatory compliance with healthcare standards such as HIPAA and GDPR.

The primary objective of this systematic review is to provide a comprehensive analysis of the current advancements in ML models for the early detection of CVDs. This review aims to; Identify and categorize ML algorithms used in CVD prediction and diagnosis. Evaluate the effectiveness of various ML models in improving early detection and risk assessment. Explore the integration of ML with diverse data sources, including EHRs, imaging modalities, and wearable technologies. Discuss the challenges and ethical considerations in deploying ML-based CVD detection systems. Highlight future research directions and innovations to enhance the clinical applicability of ML in cardiovascular healthcare. By synthesizing the latest findings in ML-driven CVD detection, this review seeks to inform researchers, clinicians, and policymakers about the potential of AI in transforming cardiovascular healthcare. The insights provided will contribute to the development of robust, accurate, and ethically sound AI-driven diagnostic systems aimed at reducing the global burden of CVDs.

II. METHODOLOGY

This systematic review follows the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) framework to ensure a structured and transparent approach in identifying, selecting, and analyzing studies on machine learning models for early detection of cardiovascular diseases. A comprehensive search was conducted across databases, including PubMed, IEEE Xplore, Scopus, Web of Science, and Google Scholar, covering studies published between 2015 and 2024. The search strategy utilized keywords such as “machine learning,” “cardiovascular disease,” “early detection,” “deep learning,” “predictive modeling,” and “artificial intelligence,” with Boolean operators applied to refine the search results.

Studies were considered eligible if they applied machine learning models for early detection of cardiovascular diseases, utilized structured datasets such as electronic health records, medical imaging, wearable device data, or genomic information, provided performance evaluation metrics such as accuracy, precision, recall, or area under the curve, and were published in English. Exclusion criteria included non-peer-reviewed articles, review papers, case reports, and studies lacking sufficient methodological transparency.

Following the database search, all retrieved records were screened for duplicates and relevance based on titles and abstracts. Full-text articles were then assessed for eligibility, and final selections were made for qualitative and quantitative synthesis. Data extraction focused on study design, machine learning models applied, data sources, sample sizes, validation techniques, performance outcomes, and limitations. Risk of bias was evaluated using the Quality Assessment of Diagnostic Accuracy Studies (QUADAS-2) tool, assessing biases in patient selection, index tests, reference standards, and study flow. Additionally, dataset imbalances and fairness issues in machine learning models were analyzed to identify potential biases affecting generalizability.

Results were synthesized by categorizing machine learning models into supervised learning techniques such as logistic regression, support vector machines, and random forests, deep learning methods including convolutional and recurrent neural networks, and hybrid approaches integrating multipl*et al*gorithms. The review also examined the effectiveness of various machine learning techniques in improving early cardiovascular disease detection, their integration with existing healthcare infrastructure, and their clinical applicability. The PRISMA methodology ensures that this review provides a rigorous and reproducible synthesis of advancements, challenges, and future research directions in AI-driven cardiovascular diagnostics.

2.0 Machine Learning Models for CVD Detection

Machine learning (ML) has emerged as a powerful tool for early detection and prediction of cardiovascular diseases (CVDs) (Nissa *et al.*, 2020). Various ML models, ranging from traditional supervised learning algorithms to advanced deep learning techniques, offer robust predictive capabilities by analyzing diverse datasets such as electronic health records (EHRs), imaging data, and wearable sensor outputs as shown in figure 1 below. Additionally, unsupervised and semi-supervised learning techniques aid in patient stratification and anomaly detection.



Figure 1: Machine Learning Models for CVD Detection

Logistic regression is a widely used statistical model for binary classification problems, such as predicting the presence or absence of CVD (Mohammed and Osman, 2021). It is particularly effective for analyzing structured clinical data, including patient demographics, cholesterol levels, and blood pressure. LR models are interpretable, allowing clinicians to understand risk factors associated with CVD. However, they may struggle with complex nonlinear relationships in data. SVMs are effective in handling high-dimensional medical datasets and can separate patients with and without CVD using a hyperplane. Kernel functions, such as radial basis function (RBF) kernels, enhance SVM's ability to model nonlinear patterns in risk factors. SVMs have shown promise in ECG signal classification and stress testing but require careful tuning of hyperparameters and computational resources for large datasets. Decision trees model decision-making processes by breaking down data into simpler subsets based on feature importance (Priyanka and Kumar, 2020). Random forests, an ensemble learning technique, improve prediction accuracy by aggregating multiple decision trees. These models have been successfully applied to classify patients based on risk factors like smoking history, hypertension, and diabetes. While RF models enhance robustness, they can be less interpretable than single decision trees.

Gradient boosting methods such as XGBoost and LightGBM are advanced tree-based models that iteratively correct prediction errors. XGBoost, known for its efficiency and scalability, has been used in clinical studies to predict heart failure and myocardial infarction with high accuracy (Du *et al*., 2020). LightGBM, optimized for large datasets, is useful for processing high-dimensional medical data efficiently while maintaining predictive performance. ANNs, inspired by the human brain, consist of interconnected neurons that process medical data in multiple layers. They are particularly effective in handling large datasets, including ECG waveforms and genomic information. ANNs have demonstrated superior performance in predicting CVD onset compared to traditional statistical models. However, their black-box nature and computational demands pose challenges for clinical adoption.

Convolutional Neural Networks (CNN) excel in analyzing medical imaging data, including echocardiograms, CT scans, and MRI images. By extracting hierarchical features, CNNs can identify patterns associated with CVD, such as arterial blockages and ventricular hypertrophy (Faizal *et al*., 2021). CNN-based models have been integrated into computer-aided diagnosis systems to support radiologists in detecting abnormalities with high precision. Recurrent Neural Networks (RNN) and Long Short-Term Memory (LSTM) networks are designed for sequential data processing, making them ideal for analyzing ECG and continuous blood pressure monitoring data. LSTM networks, with their ability to retain long-term dependencies, can predict arrhythmias, atrial fibrillation, and other cardiac anomalies. These models enhance the detection of subtle variations in heart rhythms that may indicate early-stage CVD. Transformer models, originally developed for natural language processing, have been adapted for CVD risk assessment by leveraging large-scale patient data. These models can process heterogeneous data sources, including structured EHRs and unstructured clinical notes, to generate comprehensive patient risk profiles. Transformer-based architectures, such as BERT and GPT variants, are being explored for personalized cardiovascular risk stratification (Kothinti, 2021).

Unsupervised learning techniques, such as k-means clustering and hierarchical clustering, group patients based on similar risk profiles (Grant *et al*., 2020) These methods aid in identifying high-risk subpopulations, enabling targeted prevention strategies. Clustering has been applied to segment patients based on lifestyle factors, genetic predisposition, and biomarker variations. Anomaly detection techniques, including autoencoders and isolation forests, identify deviations from normal health patterns that may indicate the early onset of CVD. Wearable devices and continuous monitoring systems leverage these methods to detect irregular heartbeats or sudden changes in blood pressure, triggering alerts for timely medical intervention. Machine learning offers a diverse set of models for early CVD detection, ranging from interpretable logistic regression to deep learning-powered diagnostic tools. Supervised learning models provide structured predictive insights, deep learning enhances medical imaging and time-series analysis, and unsupervised methods facilitate patient stratification and anomaly detection. Future research should focus on improving model transparency, integrating multi-modal patient data, and ensuring ethical deployment in clinical settings (Kalusivalingam *et al*., 2021).

2.2 Data Sources and Feature Selection in ML Models

The effectiveness of machine learning (ML) models for early cardiovascular disease (CVD) detection depends significantly on the quality and relevance of data sources (Sajid *et al*., 2021) Various data modalities, including electronic health records (EHRs), medical imaging, wearable device data, and biomarkers, contribute to developing robust predictive models. However, handling high-dimensional medical data requires efficient feature selection techniques to improve model performance and interpretability. Electronic Health Records (EHRs) serve as a primary source of structured clinical data, offering a comprehensive patient history, including demographics, medical diagnoses, medications, laboratory results, and lifestyle factors. These records facilitate longitudinal analysis, allowing ML models to identify patterns associated with CVD risk factors such as hypertension, diabetes, cholesterol levels, and smoking history. However, EHR data pose challenges such as missing values, inconsistent data entry, and interoperability issues across healthcare systems.

Medical imaging plays a crucial role in CVD diagnosis, with electrocardiograms (ECGs) being widely used to detect arrhythmias, myocardial infarctions, and other cardiac abnormalities (Xie *et al*., 2020). Echocardiography provides insights into heart structure and function, while MRI and CT scans help assess vascular conditions, including arterial plaque buildup. Convolutional Neural Networks (CNNs) are commonly employed in medical imaging analysis to extract complex patterns indicative of disease progression. The challenge with imaging data lies in the need for large annotated datasets and computationally intensive processing. Wearable devices, such as smartwatches and fitness trackers, continuously collect physiological data, including heart rate variability (HRV), blood pressure, and physical activity levels (Teixeira *et al*., 2021). These real-time data streams provide valuable insights into cardiovascular health trends and enable early detection of irregularities. ML models leveraging wearable data can identify deviations from normal patterns, predicting conditions such as atrial fibrillation or hypertension. The challenge with wearable data is variability in device accuracy, potential signal noise, and privacy concerns associated with continuous monitoring.

Biomarkers, including cholesterol levels, troponins, and inflammatory markers like C-reactive protein (CRP), provide crucial indicators of cardiovascular health. Genomic data further enhance precision medicine approaches, enabling personalized risk assessments based on genetic predisposition (Strianese *et al*., 2020). Machine learning models integrating biomarker and genetic information improve risk stratification by identifying individuals susceptible to specific CVD subtypes. However, challenges include data complexity, high dimensionality, and ethical concerns regarding genetic data usage. Given the high-dimensional nature of medical data, feature selection techniques are essential for improving ML model efficiency and interpretability. Effective feature selection reduces redundancy, enhances model generalization, and mitigates overfitting.

Principal Component Analysis (PCA) is a dimensionality reduction technique that transforms correlated variables into a smaller set of uncorrelated principal components (Salem and Hussein, 2019). By capturing the most significant variations in data, PCA helps ML models focus on key features without sacrificing predictive accuracy. PCA is particularly useful in medical imaging and genomic data analysis, where raw datasets contain thousands of features. However, PCA's drawback is the loss of direct interpretability since principal components do not always align with clinically meaningful variables. Recursive Feature Elimination (RFE) is an iterative feature selection method that ranks features based on their contribution to model performance. It systematically removes the least important features and retrains the model until an optimal subset is identified. RFE is widely used in structured clinical data and EHR-based models, ensuring that only the most relevant predictors, such as blood pressure and cholesterol levels, are included (Baccouche *et al*., 2020). The limitation of RFE is its computational intensity, particularly when applied to large datasets. Regularization techniques such as Least Absolute Shrinkage and Selection Operator (LASSO) and Ridge regression penalize less important features, effectively reducing feature space while maintaining predictive power. LASSO, in particular, enforces sparsity by setting the coefficients of irrelevant features to zero, making it ideal for handling high-dimensional biomarker and genomic datasets. Regularization techniques enhance model interpretability and prevent overfitting but require careful hyperparameter tuning. Data sources such as EHRs, medical imaging, wearable devices, and biomarkers provide a rich foundation for training ML models for CVD detection. However, the high-dimensional nature of medical data necessitates the use of feature selection techniques like PCA, RFE, and LASSO to enhance model efficiency and interpretability (Effrosynidis and Arampatzis, 2021). Future research should focus on integrating multi-modal data while addressing challenges related to data standardization, privacy, and computational demands to improve early detection of cardiovascular diseases.

2.3 Performance Evaluation of ML Models

The effectiveness of machine learning (ML) models in detecting cardiovascular diseases (CVDs) relies on rigorous performance evaluation (Mathur *et al*., 2020). Assessing model performance ensures reliability, generalizability, and clinical applicability. Various metrics such as accuracy, precision, recall, sensitivity, specificity, and the area under the receiver operating characteristic curve (AUC-ROC) are used to evaluate predictive models as shown in figure 2. Additionally, robust validation techniques, including cross-validation and external validation, enhance model credibility. A comparison with traditional risk assessment tools further highlights the advantages and limitations of ML-based approaches.

Accuracy represents the proportion of correctly classified cases (both positive and negative) out of all cases. While a high accuracy suggests good model performance, it may be misleading in imbalanced datasets where one class (e.g., non-CVD patients) is more prevalent than the other (Aggrawal and Pal, 2021). Precision, also known as Positive Predictive Value (PPV), measures the proportion of correctly predicted positive cases (CVD cases) out of all cases predicted as positive. It is critical in reducing false positives, which is essential in clinical settings where unnecessary treatments can be costly and harmful. Recall, or Sensitivity, measures the proportion of actual positive cases correctly identified by the model. A high recall is important for minimizing false negatives, ensuring that CVD patients are not misclassified as healthy (Lowres *et al.*, 2020). F1-score is the harmonic mean of precision and recall, providing a balanced measure when both false positives and false negatives need to be minimized. It is particularly useful in scenarios where class imbalance exists.



Figure 2: Metrics for assessing model effectiveness

Sensitivity (True Positive Rate) measures the ability of a model to correctly identify CVD patients. High sensitivity ensures that at-risk patients are diagnosed early, reducing the likelihood of missed diagnoses. Specificity (True Negative Rate) assesses the ability of a model to correctly classify non-CVD cases (Atasoy *et al.*, 2019). High specificity reduces unnecessary interventions by minimizing false positives. An optimal model should maintain a balance between sensitivity and specificity, depending on the clinical requirements.

Area under the receiver operating characteristic curve (AUC-ROC) curve is a widely used metric that evaluates model discrimination ability. The receiver operating characteristic (roc) curve plots the true positive rate (sensitivity) against the false positive rate (1 - specificity) at various thresholds (Bowers and Zhou, 2019). The Area Under the Curve (AUC) provides a single value summarizing the model's ability to distinguish between CVD-positive and CVD-negative cases. An AUC close to 1 indicates excellent model performance, while an AUC of 0.5 suggests that the model performs no better than random chance. The AUC-ROC metric is particularly useful in comparing different ML models to identify the most suitable one for CVD detection.

Cross-validation is essential to ensure that the ML model generalizes well to unseen data. K-fold cross-validation is a common technique where the dataset is divided into K subsets, and the model is trained and tested multiple times to obtain an average performance score (Nti *et al.*, 2021). Leave-One-Out Cross-Validation (LOOCV) is another method where one sample is used for testing while the remaining samples are used for training. While computationally expensive, LOOCV provides a robust estimate of model performance. External validation involves testing the model on an independent dataset, ensuring that performance is consistent across different populations and clinical settings (Adelodun *et al.*, 2018). External validation is crucial for regulatory approval and real-world deployment.

Traditional risk assessment tools such as the Framingham Risk Score (FRS) and Atherosclerotic Cardiovascular Disease (ASCVD) Risk Score have been widely used for predicting CVD risk. These tools rely on logistic regression models using structured clinical variables such as age, cholesterol levels, blood pressure, smoking status, and diabetes history. ML models often outperform traditional tools by incorporating a wider range of data sources, including imaging, wearable device data, and genetic markers. However, while ML models provide higher predictive accuracy, their complexity and potential lack of interpretability pose challenges in clinical adoption

(Tomassoni *et al*., 2013). Ensuring explainability through techniques such as SHapley Additive exPlanations (SHAP) and LIME (Local Interpretable Model-agnostic Explanations) can improve trust among healthcare providers. Evaluating the performance of ML models for CVD detection is critical for ensuring clinical reliability and effectiveness. Metrics such as accuracy, precision, recall, sensitivity, specificity, and AUC-ROC provide insights into model strengths and weaknesses. Cross-validation and external validation techniques enhance model robustness, while comparisons with traditional risk assessment tools demonstrate the added value of ML approaches. Future efforts should focus on balancing predictive accuracy with interpretability to facilitate the widespread adoption of ML models in cardiovascular healthcare.

2.4 Challenges and Limitations in ML-Based CVD Detection

Machine learning (ML) models have demonstrated significant potential in enhancing the early detection and diagnosis of cardiovascular diseases (CVDs) (Matthew *et al*., 2021). However, despite their advancements, several challenges and limitations hinder their widespread clinical adoption. These include issues related to data quality and availability, model interpretability, generalizability across diverse populations, and ethical and regulatory compliance as shown in figure 3. Addressing these concerns is crucial for ensuring the reliable and responsible implementation of ML-based CVD detection systems in healthcare settings.

ML models require large, high-quality datasets to achieve robust performance. However, several challenges related to data quality and availability impact their effectiveness. In many CVD datasets, there is often an uneven distribution between positive cases (patients with CVD) and negative cases (healthy individuals) (Jahun *et al*., 2021). This imbalance can lead to biased models that favor the majority class, potentially missing critical CVD cases. Techniques such as oversampling, undersampling, and synthetic data generation (e.g., Synthetic Minority Over-sampling Technique, SMOTE) are commonly used to address this issue. Incomplete patient records, missing diagnostic information, and inconsistencies in electronic health records (EHRs) present significant challenges in model training (Austin-Gabriel *et al*., 2021). Traditional imputation techniques, such as mean/mode substitution, or advanced methods like deep learning-based imputations, can help mitigate this problem. However, incomplete data may still introduce biases and reduce model reliability. Different healthcare institutions use varying data formats, terminologies, and collection methods, making it difficult to develop universally applicable models. Efforts such as the adoption of standardized data formats (e.g., Fast Healthcare Interoperability Resources, FHIR) are essential for improving model interoperability.



Figure 3: Challenges and Limitations in ML-Based CVD Detection

A critical limitation of many ML models, particularly deep learning approaches, is their "black-box" nature, which limits interpretability and explainability (Hussain *et al*., 2021). Many ML models, especially deep neural networks (DNNs), lack transparency in decision-making. While they achieve high predictive accuracy, it is often unclear how they arrive at specific predictions. This lack of interpretability makes it difficult for clinicians to trust the model's recommendations. Methods such as SHapley Additive exPlanations (SHAP), Local Interpretable Model-agnostic Explanations (LIME), and Grad-CAM (for imaging models) help enhance explainability by providing insights into which features contribute most to model predictions. However, these techniques are still evolving and may not fully address the need for transparency in medical decision-making. Healthcare providers and regulatory agencies require ML models to be interpretable before they can be integrated into clinical workflows. If clinicians cannot understand or verify model outputs, they may be hesitant to rely on ML-based recommendations for critical decisions.

The performance of ML models for CVD detection varies across different ethnic, demographic, and regional populations (Ike *et al*., 2021). Many ML models are trained on datasets that predominantly represent certain ethnic or demographic groups. This can lead to biased predictions when applied to underrepresented populations. To improve generalizability, models should be trained and validated on diverse datasets that include multiple ethnicities, age groups, and socioeconomic backgrounds. Federated learning approaches, which allow data sharing across institutions while maintaining privacy, can help in developing more representative models. Cardiovascular disease risk factors such as diet, smoking habits, air pollution exposure, and access to healthcare services differ across regions. ML models must account for these variations to provide accurate predictions across different settings.

ML-based CVD detection models must comply with stringent ethical and legal frameworks to ensure patient safety, privacy, and fairness (Oladosu *et al*., 2021). Healthcare data is highly sensitive, and its use in ML models raises concerns about patient privacy. Regulations such as the General Data Protection Regulation (GDPR) in Europe and the Health Insurance Portability and Accountability Act (HIPAA) in the U.S. mandate strict guidelines on data protection, access control, and anonymization. Ensuring compliance with these regulations is essential for legal and ethical model deployment. Unintentional biases in ML models can lead to unfair treatment of certain patient groups. Bias mitigation strategies, such as balanced dataset curation and fairness-awar*et al*gorithms, must be incorporated into model development. In cases where ML models are used for CVD diagnosis or treatment recommendations, there must be clear guidelines on accountability. Should a misdiagnosis occur, it is crucial to determine whether the responsibility lies with the model developer, healthcare provider, or data source. Establishing transparent governance frameworks can help address this challenge. Despite the promising applications of ML in early CVD detection, several challenges and limitations must be addressed before widespread clinical adoption. Issues related to data quality, model interpretability, generalizability, and regulatory compliance remain key barriers. Efforts to enhance data standardization, improve explainability, and mitigate biases will be essential for building reliable and equitable ML models for cardiovascular healthcare (Tomassoni *et al*., 2013). Future research should focus on developing ethical, transparent, and robust ML models that can seamlessly integrate into real-world clinical settings while prioritizing patient safety and trust.

2.5 Future Directions and Innovations in ML for CVD Prediction

Machine learning (ML) has emerged as a powerful tool in cardiovascular disease (CVD) prediction, offering improved diagnostic accuracy and early intervention strategies. As technology continues to evolve, several advancements are shaping the future of ML-driven cardiovascular healthcare (Kuo *et al*., 2019). Key innovations include deep learning improvements, integration with wearable devices and the Internet of Things (IoT), federated learning for privacy-preserving models, and enhanced explainability to build trust in AI-driven healthcare solutions (Tomassoni *et al*., 2013). These developments have the potential to transform how CVD is diagnosed, monitored, and managed.

Deep learning, a subset of ML, has significantly enhanced the ability to analyze complex cardiovascular data, including medical imaging, electrocardiograms (ECG), and echocardiograms (Elujide *et al*., 2021). Convolutional neural networks (cnns) for imaging analysis have shown remarkable success in interpreting medical images such as echocardiograms, MRI scans, and CT scans for CVD diagnosis. They can automatically detect anomalies such as blocked arteries, valve defects, and myocardial infarction with high precision. Future research aims to refine CNN architectures for improved diagnostic accuracy and computational efficiency. Recurrent neural networks (RNNs) and long short-term memory (LSTM), since cardiovascular health monitoring often involves sequential data (e.g., ECG readings, blood pressure fluctuations), RNNs and LSTM networks have been effective in analyzing patterns over time. Future developments may focus on hybrid models that combine CNNs and LSTMs for comprehensive cardiovascular assessments (Ajayi and Akerele, 2021). Transformer models, such as those used in natural language processing (e.g., BERT and GPT), are now being adapted for medical applications. These models can analyze large-scale patient records, genetic data, and multi-modal information, leading to highly personalized CVD risk assessments. The refinement of transformer-based architectures for clinical decision support is a promising future direction (Olamijuwon, 2020).

The rapid growth of wearable health monitoring devices, such as smartwatches and fitness trackers, has opened new avenues for real-time cardiovascular health assessment (Oyedokun, 2019). Integrating AI with wearable devices and IoT networks allows for continuous health monitoring, early disease detection, and personalized interventions. AI-driven wearable devices can track vital signs such as heart rate variability, blood pressure, oxygen saturation, and physical activity. Machine learning models can analyze these data streams to detect early warning signs of conditions like arrhythmia, hypertension, and heart failure (Hassan *et al*., 2021). Future innovations aim to improve the accuracy and sensitivity of these models. By continuously analyzing health metrics, ML models can provide personalized lifestyle recommendations and alert users to potential cardiovascular risks. This approach supports preventive healthcare and reduces the likelihood of acute cardiac events (Agho *et al*., 2021). With IoT connectivity, wearable devices can seamlessly transmit data to healthcare providers for remote monitoring. AI algorithms can assess this data in real-time, enabling proactive interventions. Future advancements in IoT and cloud computing will enhance the scalability and security of these systems.

One of the major challenges in ML-driven healthcare solutions is ensuring data privacy while maintaining model performance. Federated learning offers a promising approach to address this issue by enabling decentralized AI training without direct data sharing (Nwaozomudoh *et al*., 2021). Traditional ML models require centralized datasets, which raises concerns about data security and regulatory compliance (e.g., HIPAA, GDPR). Federated learning allows institutions to collaboratively train models on distributed datasets while keeping patient data localized. This enhances privacy and facilitates multi-institutional studies. By implementing federated learning, hospitals and research institutions worldwide can develop robust CVD prediction models without compromising patient confidentiality. Future research may focus on optimizing federated learning algorithms for healthcare applications. With advancements in mobile and edge computing, AI models can be deployed directly on wearable devices, reducing the need for cloud-based processing (Odio *et al*., 2021). This enhances data security and enables faster, real-time predictions. Future innovations may focus on improving the efficiency of AI models for low-power, on-device computing.

Despite the accuracy of AI models, their adoption in clinical settings is hindered by concerns about interpretability and trust (Dienagha *et al*., 2021). Enhancing the explainability of AI-driven healthcare solutions is a critical area of future development. Many deep learning models operate as "black boxes," making it difficult for clinicians to understand their decision-making processes. Techniques such as SHapley Additive exPlanations (SHAP), Local interpretable model-agnostic explanations (LIME), and Grad-CAM (for medical imaging) help reveal how AI models arrive at their predictions. Future research should refine these methods to improve model transparency. AI should serve as an assistive tool rather than replace human decision-making. Future advancements should focus on hybrid decision-support systems that combine AI-driven insights with clinician expertise (Oluokun, 2021). This approach can improve diagnostic confidence and patient outcomes. Establishing clear guidelines for AI deployment in healthcare is essential for ensuring safety and ethical use. Regulatory bodies such as the FDA, EMA, and WHO are actively working on AI governance frameworks. Future efforts should prioritize standardized validation protocols for AI-based CVD prediction models (Elujide *et al*., 2021). The future of ML-based CVD prediction is shaped by advancements in deep learning, integration with wearable technologies, privacy-preserving AI techniques, and improved explainability. These innovations hold the potential to revolutionize cardiovascular diagnostics, making early detection more accessible, accurate, and personalized. However, challenges such as data privacy, bias mitigation, and regulatory compliance must be addressed to ensure responsible AI adoption in healthcare. As research continues to evolve, interdisciplinary collaboration between AI experts, clinicians, and policymakers will be key to unlocking the full potential of ML in cardiovascular disease prediction and management (Adewoyin, 2021; Akinade *et al*., 2021).

CONCLUSION

This systematic review highlights the significant role of machine learning (ML) in the early detection and diagnosis of cardiovascular diseases (CVDs). Key findings indicate that ML models, including supervised learning techniques such as logistic regression (LR), support vector machines (SVM), decision trees, and deep learning approaches like convolutional neural networks (CNNs) and recurrent neural networks (RNNs), have demonstrated high accuracy in identifying CVD risk. Additionally, the integration of ML with electronic health records (EHRs), medical imaging, wearable devices, and biomarker analysis has enhanced predictive capabilities. However, challenges such as data quality, model interpretability, generalizability across diverse populations, and regulatory constraints remain critical considerations for successful implementation.

The potential impact of ML on early CVD detection and patient outcomes is profound. By leveraging AI-driven risk assessment tools, healthcare providers can detect CVD at earlier stages, allowing for timely interventions that reduce morbidity and mortality. ML models enable personalized treatment plans by analyzing individual risk factors, optimizing resourc*et al*location, and improving patient monitoring through wearable technologies and remote healthcare solutions. Furthermore, AI-enhanced predictive analytics can support clinicians in decision-making, ultimately leading to better healthcare delivery and cost reduction.

To maximize the benefits of ML in clinical settings, future research should focus on addressing data imbalance issues, enhancing model transparency through explainable AI techniques, and ensuring ethical compliance with privacy regulations. Additionally, cross-institutional collaborations using federated learning can improve model robustness while safeguarding patient confidentiality. For successful clinical integration, ML algorithms should be rigorously validated against traditional risk assessment tools and implemented in real-world healthcare workflows. By overcoming these challenges, ML has the potential to revolutionize cardiovascular healthcare, making early diagnosis more accessible and improving patient outcomes on a global scale.

REFERENCES

[1] Adelodun, A.M., Adekanmi, A.J., Roberts, A. and Adeyinka, A.O., 2018. Effect of asymptomatic malaria parasitemia on the uterine and umbilical artery blood flow impedance in third-trimester singleton Southwestern Nigerian pregnant women. *Tropical Journal of Obstetrics and Gynaecology*, *35*(3), pp.333-341.

[2] Adewoyin, M.A., 2021. Developing frameworks for managing low-carbon energy transitions: overcoming barriers to implementation in the oil and gas industry.

[3] Aggrawal, R. and Pal, S., 2021. Elimination and backward selection of features (P-value technique) in prediction of heart disease by using machine learning algorithms. *Turkish Journal of Computer and Mathematics Education (TURCOMAT)*, *12*(6), pp.2650-2665.

[4] Agho, G., Ezeh, M.O., Isong, M., Iwe, D. and Oluseyi, K.A., 2021. Sustainable pore pressure prediction and its impact on geo-mechanical modelling for enhanced drilling operations. *World Journal of Advanced Research and Reviews*, *12*(1), pp.540-557.

[5] Ahmed, Z., Mohamed, K., Zeeshan, S. and Dong, X., 2020. Artificial intelligence with multi-functional machine learning platform development for better healthcare and precision medicine. *Database*, *2020*, p.baaa010.

[6] Ajayi, A. and Akerele, J.I., 2021. A high-impact data-driven decisionmaking model for integrating cutting-edge cybersecurity strategies into public policy, governance, and organizational frameworks. *International Journal of Multidisciplinary Research and Growth Evaluation*, *2*(1), pp.623-637.

[7] Akinade, A.O., Adepoju, P.A., Ige, A.B., Afolabi, A.I. and Amoo, O.O., 2021. A conceptual model for network security automation: Leveraging AI-driven frameworks to enhance multi-vendor infrastructure resilience. *International Journal of Science and Technology Research Archive*, *1*(1), pp.39-59.

[8] Alli, O.I. and Dada, S.A., 2021. Innovative Models for Tobacco Dependency Treatment: A Review of Advances in Integrated Care Approaches in High-Income Healthcare Systems. *IRE Journals*, *5*(6), pp.273-282.

[9] Atasoy, S., Johar, H., Peters, A. and Ladwig, K.H., 2019. Association of hypertension cut-off values with 10-year cardiovascular mortality and clinical consequences: a real-world perspective from the prospective MONICA/KORA study. *European heart journal*, *40*(9), pp.732-738.

[10] Atta, J.A., Al Zoubi, M.A.M., Temedie-Asogwa, T. and Amafah, J., Comparing the Cost-Effectiveness of Pharmaceutical vs. Non-Pharmaceutical Interventions for Diabetes Management.

[11] Austin-Gabriel, B., Hussain, N.Y., Ige, A.B., Adepoju, P.A., Amoo, O.O. and Afolabi, A.I., 2021. Advancing zero trust architecture with AI and data science for enterprise cybersecurity frameworks. *Open Access Research Journal of Engineering and Technology*, *1*(01), pp.047-055.

[12] Baccouche, A., Garcia-Zapirain, B., Castillo Olea, C. and Elmaghraby, A., 2020. Ensemble deep learning models for heart disease classification: A case study from Mexico. *Information*, *11*(4), p.207.

[13] Bayyapu, S., Turpu, R.R. and Vangala, R.R., 2019. Advancing healthcare decision-making: The fusion of machine learning, predictive analytics, and cloud technology. *International Journal of Computer Engineering and Technology (IJCET)*, *10*(5), pp.157-170.

[14] Bidemi, A.I., Oyindamola, F.O., Odum, I., Stanley, O.E., Atta, J.A., Olatomide, A.M., Nnamdi, N.C., Amafah, J. and Helen, O.O., 2021. Challenges Facing Menstruating Adolescents: A Reproductive Health Approach. *Journal of Adolescent Health*, *68*(5), pp.1-10.

[15] Bowers, A.J. and Zhou, X., 2019. Receiver operating characteristic (ROC) area under the curve (AUC): A diagnostic measure for evaluating the accuracy of predictors of education outcomes. *Journal of Education for Students Placed at Risk (JESPAR)*, *24*(1), pp.20-46.

[16] Chen, S., Qi, J., Fan, S., Qiao, Z., Yeo, J.C. and Lim, C.T., 2021. Flexible wearable sensors for cardiovascular health monitoring. *Advanced Healthcare Materials*, *10*(17), p.2100116.

[17] Dienagha, I.N., Onyeke, F.O., Digitemie, W.N. and Adekunle, M., 2021. Strategic reviews of greenfield gas projects in Africa: Lessons learned for expanding regional energy infrastructure and security.

[18] Dirlikov, E., Jahun, I., Odafe, S.F., Obinna, O., Onyenuobi, C., Ifunanya, M., Efuntoye, T.A., Tingir, N., Ene, U., Fagbemi, A. and Meribe, C., 2021. Section navigation rapid scale-up of an antiretroviral therapy program before and during the COVID-19 pandemic-nine states, Nigeria, March 31, 2019-September 30, 2020.

[19] Du, Z., Yang, Y., Zheng, J., Li, Q., Lin, D., Li, Y., Fan, J., Cheng, W., Chen, X.H. and Cai, Y., 2020. Accurate prediction of coronary heart disease for patients with hypertension from electronic health records with big data and machine-learning methods: model development and performance evaluation. *JMIR medical informatics*, *8*(7), p.e17257.

[20] Effrosynidis, D. and Arampatzis, A., 2021. An evaluation of feature selection methods for environmental data. *Ecological Informatics*, *61*, p.101224.

[21] Elagizi, A., Kachur, S., Carbone, S., Lavie, C.J. and Blair, S.N., 2020. A review of obesity, physical activity, and cardiovascular disease. *Current obesity reports*, *9*, pp.571-581.

[22] Elujide, I., Fashoto, S.G., Fashoto, B., Mbunge, E., Folorunso, S.O. and Olamijuwon, J.O., 2021. Informatics in Medicine Unlocked.

[23] Elujide, I., Fashoto, S.G., Fashoto, B., Mbunge, E., Folorunso, S.O. and Olamijuwon, J.O., 2021. Application of deep and machine learning techniques for multi-label classification performance on psychotic disorder

diseases. *Informatics in Medicine Unlocked*, *23*, p.100545.

[24] Faizal, A.S.M., Thevarajah, T.M., Khor, S.M. and Chang, S.W., 2021. A review of risk prediction models in cardiovascular disease: conventional approach vs. artificial intelligent approach. *Computer methods and programs in biomedicine*, *207*, p.106190.

[25] Grant, R.W., McCloskey, J., Hatfield, M., Uratsu, C., Ralston, J.D., Bayliss, E. and Kennedy, C.J., 2020. Use of latent class analysis and k-means clustering to identify complex patient profiles. *JAMA network open*, *3*(12), pp.e2029068-e2029068.

[26] Hassan, Y.G., Collins, A., Babatunde, G.O., Alabi, A.A. and Mustapha, S.D., 2021. AI-driven intrusion detection and threat modeling to prevent unauthorized access in smart manufacturing networks. *Artificial intelligence (AI)*, p.16.

[27] Hurley, N.C., Spatz, E.S., Krumholz, H.M., Jafari, R. and Mortazavi, B.J., 2020. A survey of challenges and opportunities in sensing and analytics for risk factors of cardiovascular disorders. *ACM transactions on computing for healthcare*, *2*(1), pp.1-42.

[28] Hussain, N.Y., Austin-Gabriel, B., Ige, A.B., Adepoju, P.A., Amoo, O.O. and Afolabi, A.I., 2021. AI-driven predictive analytics for proactive security and optimization in critical infrastructure systems. *Open Access Research Journal of Science and Technology*, *2*(02), pp.006-015.

[29] Ike, C.C., Ige, A.B., Oladosu, S.A., Adepoju, P.A., Amoo, O.O. and Afolabi, A.I., 2021. Redefining zero trust architecture in cloud networks: A conceptual shift towards granular, dynamic access control and policy enforcement. *Magna Scientia Advanced Research and Reviews*, *2*(1), pp.074-086.

[30] Jahun, I., Dirlikov, E., Odafe, S., Yakubu, A., Boyd, A.T., Bachanas, P., Nzelu, C., Aliyu, G., Ellerbrock, T., Swaminathan, M. and CDC Nigeria ART Surge Team, 2021. Ensuring optimal community HIV testing services in Nigeria using an enhanced community case-finding package (ECCP), October 2019–March 2020: acceleration to HIV epidemic control. *HIV/AIDS-Research and Palliative Care*, pp.839-850.

[31] Jahun, I., Said, I., El-Imam, I., Ehoche, A., Dalhatu, I., Yakubu, A., Greby, S., Bronson, M., Brown, K., Bamidele, M. and Boyd, A.T., 2021. Optimizing community linkage to care and antiretroviral therapy Initiation: Lessons from the Nigeria HIV/AIDS Indicator and Impact Survey (NAIIS) and their adaptation in Nigeria ART Surge. *PLoS One*, *16*(9), p.e0257476.

[32] Kalusivalingam, A.K., Sharma, A., Patel, N. and Singh, V., 2021. Enhancing Diagnostic Accuracy in Medical Imaging through Convolutional Neural Networks and Transfer Learning Algorithms. *International Journal of AI and ML*, *2*(3).

[33] Khosrow Tayebati, S., Ejike Nwankwo, I. and Amenta, F., 2013. Intranasal drug delivery to the central nervous system: present status and future outlook. *Current pharmaceutical design*, *19*(3), pp.510-526.

[34] Khosrow Tayebati, S., Tomassoni, D., Ejike Nwankwo, I., Di Stefano, A., Sozio, P., Serafina Cerasa, L. and Amenta, F., 2013. Modulation of monoaminergic transporters by choline-containing phospholipids in rat brain. *CNS & Neurological Disorders-Drug Targets (Formerly Current Drug Targets-CNS & Neurological Disorders)*, *12*(1), pp.94-103.

[35] Kothinti, R.R., 2021. Advancements in natural language processing for automated phenotyping and predictive analytics in oncology EHRS. *Iconic Research and Engineering Journals*, *8*(8), pp.245-252.

[36] Kuo, Y.M., Nwankwo, E.I., Nussbaum, R.L., Rogers, J. and Maccecchini, M.L., 2019. Translational inhibition of α-synuclein by Posiphen normalizes distal colon motility in transgenic Parkinson mice. *American journal of neurodegenerative disease*, *8*(1), p.1.

[37] Lowres, N., Duckworth, A., Redfern, J., Thiagalingam, A. and Chow, C.K., 2020. Use of a machine learning program to correctly triage incoming text messaging replies from a cardiovascular text–based secondary prevention

program: feasibility study. *JMIR mHealth and uHealth*, *8*(6), p.e19200.

[38] Mathur, P., Srivastava, S., Xu, X. and Mehta, J.L., 2020. Artificial intelligence, machine learning, and cardiovascular disease. *Clinical Medicine Insights: Cardiology*, *14*, p.1179546820927404.

[39] Matthew, A., Opia, F.N., Matthew, K.A., Kumolu, A.F. and Matthew, T.F., 2021. Cancer Care Management in the COVID-19 Era: Challenges and adaptations in the global south. *Cancer*, *2*(6).

[40] Matthew, K.A., AKINWALE, F.M., OPIA, F.N. and Adenike, A., 2021. The Relationship between oral Contraceptive Use, Mammographic Breast Density, and Breast Cancer Risk.

[41] Mohammed, E.M. and Osman, E.G.A., 2021, February. Comparison between neural networks and binary logistic regression for classification observation (case study: risk factors for cardiovascular disease). In *2020 International Conference on Computer, Control, Electrical, and Electronics Engineering (ICCCEEE)* (pp. 1-6). IEEE.

[42] Nasuti, C., Falcioni, M.L., Nwankwo, I.E., Cantalamessa, F. and Gabbianelli, R., 2008. Effect of permethrin plus antioxidants on locomotor activity and striatum in adolescent rats. *Toxicology*, *251*(1-3), pp.45-50.

[43] Nissa, N., Jamwal, S. and Mohammad, S., 2020. Early detection of cardiovascular disease using machine learning techniques an experimental study. *Int. J. Recent Technol. Eng*, *9*(3), pp.635-641.

[44] Nti, I.K., Nyarko-Boateng, O. and Aning, J., 2021. Performance of machine learning algorithms with different K values in K-fold cross-validation. *International Journal of Information Technology and Computer Science*, *13*(6), pp.61-71.

[45] Nwaozomudoh, M.O., Odio, P.E., Kokogho, E., Olorunfemi, T.A., Adeniji, I.E. and Sobowale, A., 2021. Developing a conceptual framework for enhancing interbank currency operation accuracy in Nigeria's banking sector. *International Journal of Multidisciplinary Research and Growth Evaluation*, *2*(1), pp.481-494.

[46] Odio, P.E., Kokogho, E., Olorunfemi, T.A., Nwaozomudoh, M.O., Adeniji, I.E. and Sobowale, A., 2021. Innovative financial solutions: A conceptual framework for expanding SME portfolios in Nigeria's banking sector. *International Journal of Multidisciplinary Research and Growth Evaluation*, *2*(1), pp.495-507.

[47] Oladosu, S.A., Ike, C.C., Adepoju, P.A., Afolabi, A.I., Ige, A.B. and Amoo, O.O., 2021. The future of SD-WAN: A conceptual evolution from traditional WAN to autonomous, self-healing network systems. *Magna Scientia Advanced Research and Reviews*.

[48] Olamijuwon, O.J., 2020. *Real-time Vision-based Driver Alertness Monitoring using Deep Neural Network Architectures* (Master's thesis, University of the Witwatersrand, Johannesburg (South Africa)).

[49] Oluokun, O.A., 2021. *Design of a Power System with Significant Mass and Volume Reductions, Increased Efficiency, and Capability for Space Station Operations Using Optimization Approaches* (Doctoral dissertation, McNeese State University).

[50] Oyedokun, O.O., 2019. *Green human resource management practices and its effect on the sustainable competitive edge in the Nigerian manufacturing industry (Dangote)* (Doctoral dissertation, Dublin Business School).

[51] Priyanka and Kumar, D., 2020. Decision tree classifier: a detailed survey. *International Journal of Information and Decision Sciences*, *12*(3), pp.246-269.

[52] Rudski, L., Januzzi, J.L., Rigolin, V.H., Bohula, E.A., Blankstein, R., Patel, A.R., Bucciarelli-Ducci, C., Vorovich, E., Mukherjee, M., Rao, S.V. and Beanlands, R., 2020. Multimodality imaging in evaluation of cardiovascular complications in patients with COVID-19: JACC scientific expert panel. *Journal of the American College of Cardiology*, *76*(11), pp.1345-1357.

[53] Sajid, M.R., Muhammad, N., Zakaria, R., Shahbaz, A., Bukhari, S.A.C., Kadry, S. and Suresh, A., 2021. Nonclinical features in

predictive modeling of cardiovascular diseases: a machine learning approach. *Interdisciplinary Sciences: Computational Life Sciences*, *13*, pp.201-211.

[54] Salem, N. and Hussein, S., 2019. Data dimensional reduction and principal components analysis. *Procedia Computer Science*, *163*, pp.292-299.

[55] Serhani, M.A., T. El Kassabi, H., Ismail, H. and Nujum Navaz, A., 2020. ECG monitoring systems: Review, architecture, processes, and key challenges. *Sensors*, *20*(6), p.1796.

[56] Strianese, O., Rizzo, F., Ciccarelli, M., Galasso, G., D'Agostino, Y., Salvati, A., Del Giudice, C., Tesorio, P. and Rusciano, M.R., 2020. Precision and personalized medicine: how genomic approach improves the management of cardiovascular and neurodegenerative disease. *Genes*, *11*(7), p.747.

[57] Suryadevara, S. and Yanamala, A.K.Y., 2020. Fundamentals of Artificial Neural Networks: Applications in Neuroscientific Research. *Revista de Inteligencia Artificial en Medicina*, *11*(1), pp.38-54.

[58] Teixeira, E., Fonseca, H., Diniz-Sousa, F., Veras, L., Boppre, G., Oliveira, J., Pinto, D., Alves, A.J., Barbosa, A., Mendes, R. and Marques-Aleixo, I., 2021. Wearable devices for physical activity and healthcare monitoring in elderly people: a critical review. *Geriatrics*, *6*(2), p.38.

[59] Tomassoni, D., Amenta, F., Amantini, C., Farfariello, V., Di Cesare Mannelli, L., Nwankwo, I.E., Marini, C. and Tayebati, S.K., 2013. Brain activity of thioctic acid enantiomers: in vitro and in vivo studies in an animal model of cerebrovascular injury. *International Journal of Molecular Sciences*, *14*(3), pp.4580-4595.

[60] Tomassoni, D., Amenta, F., Di Cesare Mannelli, L., Ghelardini, C., Nwankwo, I.E., Pacini, A. and Tayebati, S.K., 2013. Neuroprotective activity of thioctic acid in central nervous system lesions consequent to peripheral nerve injury. *BioMed Research International*, *2013*(1), p.985093.

[61] Tomassoni, D., Catalani, A., Cinque, C., Antonietta Di Tullio, M., Khosrow Tayebati, S., Cadoni, A., Ejike Nwankwo, I., Traini, E. and Amenta, F., 2012. Effects of cholinergic enhancing drugs on cholinergic transporters in the brain and peripheral blood lymphocytes of spontaneously hypertensive rats. *Current Alzheimer Research*, *9*(1), pp.120-127.

[62] Tomassoni, D., Nwankwo, I.E., Gabrielli, M.G., Bhatt, S., Muhammad, A.B., Lokhandwala, M.F., Tayebati, S.K. and Amenta, F., 2013. Astrogliosis in the brain of obese Zucker rat: a model of metabolic syndrome. *Neuroscience letters*, *543*, pp.136-141.

[63] Xie, L., Li, Z., Zhou, Y., He, Y. and Zhu, J., 2020. Computational diagnostic techniques for electrocardiogram signal analysis. *Sensors*, *20*(21), p.6318.